網頁

星期四, 1月 05, 2017

WuXi NextCODE Selected as Genomics Platform for Singapore Precision Medicine Effort

WuXi NextCODE Selected as Genomics Platform for Singapore Precision Medicine Effort
Leading national stakeholders choose the global standard in large-scale genomics to propel innovation in sequence-based digital health and medicine in Singapore and Southeast Asia

- National Heart Centre Singapore (NHCS), together with SingHealth Duke-NUS Institute of Precision Medicine (PRISM) and Infocomm Media Development Authority (IMDA), spearheads vanguard population precision medicine program

- WuXi NextCODE to install massively scalable database, analytics and reporting suite at NHCS

- Pilot study aims to identify genetic risk factors and novel means to address heart disease risk

- WuXi NextCODE's cloud-based infrastructure will integrate seamlessly into digital health strategies and enable collaboration with other national genomics efforts around the world

NEWS PROVIDED BY
Jan 05, 2017, 07:08 ET
SINGAPORE and SHANGHAI and CAMBRIDGE, Mass. and REYKJAVIK, Iceland, Jan. 5, 2017 /PRNewswire/ -- WuXi NextCODE, the contract genomics organization enabling precision medicine worldwide, and the National Heart Centre Singapore (NHCS), a leading national and regional cardiovascular medicine center, today announced their partnership to advance population-based genomic research and precision medicine applications in Singapore.
This marks an important first step in a national precision medicine initiative that brings together NHCS as a leading research hospital in cardiovascular disease, SingHealth Duke-NUS PRISM, as the institutional flagship program on Precision Medicine, and the IMDA, as a part of its mission to advance Singapore's Smart Nation vision. In addition to co-funding the project, IMDA scoped the initiative's technical requirements. WuXi NextCODE was awarded by NHCS following a competitive review of leading global genomics platforms.
Under the partnership, WuXi NextCODE will create an instantly queriable cloud-based enterprise data warehouse integrating large-scale whole genome sequence, medical and wearables data from both cardiovascular patients and healthy control subjects recruited by NHCS. This proof-of-concept resource will power research into novel genetic risk factors for heart disease in the Singapore and Southeast Asia populations more broadly. It will also enable the generation of clinical reports offering actionable insights on different types of genetic risk, carrier status and drug response, with the aim of informing personalized health and wellness. The partnership contemplates expanding from heart disease into other disease types, and WuXi NextCODE's infrastructure is scalable to hundreds of thousands of participants.
"We are honored to be chosen by such visionary partners to innovate cutting-edge precision medicine in Singapore," said Hannes Smarason, COO of WuXi NextCODE. "We are the backbone for leading precision medicine projects in the US, Europe, China and the Middle East, and Singapore's leadership in digital convergence and healthcare provides a unique opportunity to advance our technology in new ways to benefit patients and people here and across the region."
"NHCS is delighted to partner with IMDA and WuXi NextCODE in this pilot project," commented Associate Professor Yeo Khung Keong, Senior Consultant, Department of Cardiology, National Heart Centre Singapore. "We believe that the scientific and technical expertise that WuXi NextCODE provides will enable us to integrate precision medicine into clinical care and medical research. I am very much looking forward to this collaboration."

"IMDA seeks to enhance Singapore's technology capabilities through the use of infocomm media to improve the lives of citizens and enhance businesses. Our collaboration with partners such as WuXi NextCODE in bioinformatics is one example of using Singapore as a testbed to develop new innovative technological solutions that bring significant benefits and create high value-added jobs and businesses for ICM professionals in the health and pharmaceutical industries. Creating and applying new infocomm media technologies in healthcare and wellness is an important aspect of Singapore's Smart Nation journey," said Mr Khoong Hock Yun, Assistant Chief Executive (Development), IMDA.